I ntroduction: Women with Polycystic Ovary Syndrome (PCOS) are at increased risk for cardiovascular morbidity and metabolic disorders including: dyslipidaemia, hypertension, insulin resistance, gestational diabetes, type 2 diabetes, systemic inflammation and endothelial dysfunction. The prevalence of obesity and insulin resistance in women with PCOS is significantly higher compared to the general population. Lipid accumulation product is a new, cheap and easily available predictor for metabolic syndrome both in general population and in women with PCOS. Materials and methods: The study included 50 patients at the Clinic of Endocrinology, Diabetes and Metabolic Disorders, Clinical Center University of Sarajevo. All patients were diagnosed with PCOS according to the Rotterdam ES-HRE criteria and were divided into two groups according to their body mass index (BMI). A prospective study established the following parameters: anthropometric measurements (waist circumference, height, weight), BMI, and serum triglycerides and insulin resistance. LAP was calculated using the formula: LAP (women) = [waist circumference (cm)-58] × [triglycerides (mmol/L)]. Results: Waist circumference in women with BMI ≤ 24.9 kg/m2 was 31 cm lower than waist circumference in women with a BMI > 25 kg/m2. Mean triglyceride value of the patients in group BMI ≤ 24.9 kg/m2 was 1.15 mmol/l lower than the mean value of triglycerides in women with a BMI >25 kg/m2. Insulin resistance was present in 66.7% in group with BMI ≤ 24.9 kg/m2, and in 75.0% in the group with BMI>25.0 kg/m2. LAP was shown to be a marker for the differentiation of insulin-resistant and nonresistant patients with a cut-off value of 17.91. Conclusion: Patients with PCOS and BMI ≤ 24.9 kg/m2 were significantly different from those with BMI>25 kg/m2 in the values of body weight, waist circumference and triglycerides. There was no statistically significant difference in insulin resistance. LAP values were higher in patients in the group with BMI > 25 kg/m2. LAP was a marker for differentiation of insulin -resistant and non-resistant women with PCOS.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a reproductive endocrinopathy and metabolic disorder affecting 5-8% of women in reproductive age. In younger women with PCOS the most prevalent feature is hyperandrogenism. Characteristics of older women with PCOS include obesity, cardiovascular and metabolic risk factors. Women with PCOS are at increased risk for dyslipidaemia, hypertension, insulin resistance, gestational diabetes, type 2 diabetes, systemic inflammation and endothelial dysfunction, and the increased risk for cardiovascular morbidity (1) . Body mass index (BMI) is used as a medical standard of obesity, and is used in the statistics of the World Health Organization. It is calculated by dividing the body weight (kg) by the square of body height (m 2 ). The prevalence of insulin resistance in women with PCOS is significantly higher compared to the general population. Lipid accumulation product (LAP) is considered a reliable indicator of risk for cardiovascular disease in women with PCOS (2 
ReSULTS
The group with BMI ≤ 24. 9 Figure 2 ).
Lipid accumulation product is proven to be a marker for the differentiation of insulin-resistant and insulin-nonresistant patients (p = 0.049). Cut-off value for LAP is 17.91 (test sensitivity 97%, specificity 50%), as shown in Table 1 
DISCUSSION
Unlike earlier studies of Legro et al., Robinson et al. (5, 6) in which the metabolic disorders in women with PCOS were compared to those of healthy women, this study compared the metabolic disturbances of PCOS patients divided into two groups with regard to their BMI.
Women with PCOS are often overweight, and there are conflicting opinions in the literature whether patients are obese due to PCOS, or pre-obese women have a predisposition to PCOS. Hoegen and Oberfield study (7) investigated this dilemma. There is evidence to indicate slow metabolism and subsequent predisposition to obesity in women with PCOS. In contrast, the literature found no link between excess weight and PCOS, but the difference in obesity rates between countries is explained by environmental factors and sedentary lifestyle. The patients in this study were divided into two groups, and evaluated for the uniformity of characteristics that could have an impact on the results of laboratory tests. They were uniform in age, body height and dietary habits. The basic difference between the two groups was value of body weight, and anthropometric measurements including waist circumference. Having examined the lipid profile of the patients in the sample, it was shown that the values of triglycerides were higher in patients in the group with BMI > 25 kg/ m 2 . Kauffman et al. (8) had shown that overweight women with PCOS are significantly affected by dyslipidemia, with increased level of triglycerides, which correlates with the results of our study.
Our study showed that women in both groups had a uniform incidence of insulin resistance. The incidence of insulin resistance in patients in the sample was 70.0%, which is slightly higher than the results of the study by Pontes et al. (9) where insulin resistance was present in 56.4% of women with PCOS. Comparing the patients with PCOS and a group of healthy women, Sarapatková et al. (10) found that patients with PCOS require a greater amount of insulin to maintain normoglycemia. Karabulut et al. (11) showed that increased BMI and type of abdominal (central) obesity in women with PCOS is very closely associated with insulin resistance. Of great importance was the finding that 66.7% of women in the group with BMI ≤ 24.9 kg/m 2 had insulin resistance. This data correlates with the results of study of Kim et al. (12) , which proved defective glucose metabolism in patients with PCOS with normal weight.
LAP is confirmed as a marker for differentiation of insulin-resistant and insulin-nonresistant patients regardless of their BMI, with the upper limit (cut-off) value of 17.81. These results correlate with the study of Wehr et al. (13) wher LAP is shown to be a readily available and inexpensive marker linked with glucose metabolism disturbances in patients with PCOS as well as women without PCOS.
CONCLUSION
Patients with PCOS and BMI ≤ 24.9 kg/m 2 were not significantly different from those with a BMI > 25 kg/m 2 in relation to age and dietary habits. Regardless of this, patients with PCOS and BMI ≤ 24.9 kg/m 2 were significantly different from those with BMI>25 kg/ m 2 in the values of body weight, waist circumference and values of triglycerides. There was no statistically significant difference in presence of insulin resistance with regard to BMI of the patients. The values of lipid accumulation product (LAP) were higher in patients in the group with BMI > 25 kg/ m 2 . LAP is a marker for differentiation of insulin -resistant and insulin nonresistant women with PCOS.
